These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21620801)

  • 1. Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.
    Ueda Y; Mori K; Ariumi Y; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2011 Jun; 409(4):663-8. PubMed ID: 21620801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
    Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
    Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient replication systems for hepatitis C virus using a new human hepatoma cell line.
    Kato N; Mori K; Abe K; Dansako H; Kuroki M; Ariumi Y; Wakita T; Ikeda M
    Virus Res; 2009 Dec; 146(1-2):41-50. PubMed ID: 19720094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris.
    Ueda Y; Mori K; Satoh S; Dansako H; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2014 May; 447(2):341-5. PubMed ID: 24726408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication.
    Dansako H; Ikeda M; Abe K; Mori K; Takemoto K; Ariumi Y; Kato N
    Virus Res; 2008 Oct; 137(1):72-9. PubMed ID: 18602954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
    Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.
    Mori K; Ueda Y; Ariumi Y; Dansako H; Ikeda M; Kato N
    Virus Genes; 2012 Jun; 44(3):374-81. PubMed ID: 22252251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.
    Ueda Y; Takeda M; Mori K; Dansako H; Wakita T; Kim HS; Sato A; Wataya Y; Ikeda M; Kato N
    PLoS One; 2013; 8(8):e72519. PubMed ID: 24023620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
    Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
    Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
    Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
    Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
    Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
    Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
    Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Replication of hepatitis C virus genome].
    Kato N
    Uirusu; 2008 Dec; 58(2):191-8. PubMed ID: 19374197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.
    Matsuno K; Ueda Y; Fukuda M; Onoda K; Waki M; Ikeda M; Kato N; Miyachi H
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4276-80. PubMed ID: 25086684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
    Bourne N; Pyles RB; Yi M; Veselenak RL; Davis MM; Lemon SM
    Antiviral Res; 2005 Aug; 67(2):76-82. PubMed ID: 15927278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
    Yano M; Ikeda M; Abe K; Dansako H; Ohkoshi S; Aoyagi Y; Kato N
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2016-27. PubMed ID: 17420205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
    Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
    Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
    Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
    J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
    Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
    Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.